Free Trial

BioCryst Pharmaceuticals (BCRX) Earnings Date, Estimates & Call Transcripts

BioCryst Pharmaceuticals logo
$7.60 +0.11 (+1.47%)
(As of 11/22/2024 ET)

BioCryst Pharmaceuticals Latest Earnings Summary

Upcoming Q4
Earnings Date
Feb. 24Estimated
Actual EPS
(Nov. 4)
-$0.07
Consensus EPS
(Nov. 4)
-$0.07

BioCryst Pharmaceuticals released Q3 2024 earnings on November 4, 2024, reporting an EPS of -$0.07, which hit the consensus estimate of -$0.07. Quarterly revenue rose 35.1% year-over-year to $117.10 million, above analysts' expectations of $113.99 million. With a trailing EPS of -$0.61, BioCryst Pharmaceuticals' earnings are expected to grow next year, from ($0.38) to ($0.06) per share.

BCRX Upcoming Earnings

BioCryst Pharmaceuticals' next earnings date is estimated for Monday, February 24, 2025, based off prior year's reporting schedules.

Get BioCryst Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioCryst Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

BCRX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

BCRX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

BioCryst Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241-$0.19-$0.19-$0.19
Q2 20241-$0.14-$0.14-$0.14
Q3 20241-$0.03-$0.03-$0.03
Q4 20241-$0.01-$0.01-$0.01
FY 20244($0.37)($0.37)($0.37)

BioCryst Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
2/24/2025
(Estimated)
------- 
11/4/2024Q3 2024-$0.07-$0.07--$0.07$113.99M$117.10M        
8/5/2024Q2 2024-$0.17-$0.06+$0.11-$0.06$98.30M$109.30M        
5/6/2024Q1 2024-$0.23-$0.17+$0.06-$0.17$85.62M$92.80M        
2/26/2024Q4 2023-$0.24-$0.28 -$0.04-$0.25$89.19M$93.40M    
11/2/2023Q3 2023-$0.25-$0.19+$0.06-$0.19$86.54M$86.74M    
8/3/2023Q2 2023-$0.25-$0.24+$0.01-$0.08$81.42M$81.01M        
5/3/2023Q1 2023-$0.30-$0.28+$0.02-$0.28$71.44M$68.80M        
2/21/2023Q4 2022-$0.19-$0.38 -$0.19-$0.38$74.18M$79.50M        

BioCryst Pharmaceuticals Earnings - Frequently Asked Questions

BioCryst Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 24th, 2025 based off last year's report dates. Learn more on BCRX's earnings history.

In the previous quarter, BioCryst Pharmaceuticals (NASDAQ:BCRX) reported ($0.07) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.07). Learn more on analysts' earnings estimate vs. BCRX's actual earnings.

The conference call for BioCryst Pharmaceuticals's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for BioCryst Pharmaceuticals's latest earnings report can be read online.
Read Transcript

BioCryst Pharmaceuticals (NASDAQ:BCRX) has a recorded annual revenue of $331.41 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) has a recorded net income of -$226.54 million. BCRX has generated -$0.61 earnings per share over the last four quarters.

BioCryst Pharmaceuticals's earnings are expected to grow from ($0.38) per share to ($0.06) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:BCRX) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners